Global Drug Repositioning Market Growth (Status and Outlook) 2025-2031

Global Drug Repositioning Market Growth (Status and Outlook) 2025-2031

The global Drug Repositioning market size is predicted to grow from US$ 28150 million in 2025 to US$ 37460 million in 2031; it is expected to grow at a CAGR of 4.9% from 2025 to 2031.

Drug repurposing (also called drug repositioning, reprofiling or re-tasking) is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. This strategy offers various advantages over developing an entirely new drug for a given indication.

Global Drug Repositioning key players include Teva, Novartis, Mylan, Johnson & Johnson, Pfizer, etc. Global top five manufacturers hold a share about 15%.

North America is the largest market, with a share about 40%, followed by Europe and China, both have a share over 30 percent.

In terms of product, Generic Drugs is the largest segment, with a share about 65%. And in terms of application, the largest application is Cancer, followed by Cardiovascular Diseases.

LPI (LP Information)' newest research report, the “Drug Repositioning Industry Forecast” looks at past sales and reviews total world Drug Repositioning sales in 2024, providing a comprehensive analysis by region and market sector of projected Drug Repositioning sales for 2025 through 2031. With Drug Repositioning sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drug Repositioning industry.

This Insight Report provides a comprehensive analysis of the global Drug Repositioning landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Drug Repositioning portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drug Repositioning market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drug Repositioning and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drug Repositioning.

This report presents a comprehensive overview, market shares, and growth opportunities of Drug Repositioning market by product type, application, key players and key regions and countries.

Segmentation by Type:
Generic Drugs
Clinical Trial Failed Drugs

Segmentation by Application:
Cardiovascular Diseases
Mental Illness
Cancer
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva
Novartis
Mylan
Johnson & Johnson
Pfizer
Bausch Health
GSK
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma

Please note: The report will take approximately 2 business days to prepare and deliver.